These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 35941422)

  • 1. Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study.
    Engvall K; Gréen H; Fredrikson M; Lagerlund M; Lewin F; Åvall-Lundqvist E
    Breast Cancer Res Treat; 2022 Oct; 195(3):379-391. PubMed ID: 35941422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxane-induced peripheral neuropathy and quality of life in breast cancer patients.
    Salehifar E; Janbabaei G; Alipour A; Tabrizi N; Avan R
    J Oncol Pharm Pract; 2020 Sep; 26(6):1421-1428. PubMed ID: 31937190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reliability and Validity of the EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale) among Thai Women with Breast Cancer Undergoing Taxane-Based Chemotherapy.
    Rattanakrong N; Thipprasopchock S; Siriphorn A; Boonyong S
    Asian Pac J Cancer Prev; 2022 May; 23(5):1547-1553. PubMed ID: 35633537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent neuropathy among early-stage breast cancer survivors in a population-based cohort.
    Engvall K; Gréen H; Fredriksson M; Åvall-Lundqvist E
    Br J Cancer; 2021 Aug; 125(3):445-457. PubMed ID: 34017086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.
    Bland KA; Kirkham AA; Bovard J; Shenkier T; Zucker D; McKenzie DC; Davis MK; Gelmon KA; Campbell KL
    Clin Breast Cancer; 2019 Dec; 19(6):411-422. PubMed ID: 31601479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-Induced Peripheral Neuropathy (CIPN) as a Predictor of Decreased Quality of Life in Testicular Germ Cell Tumor Survivors.
    Orszaghova Z; Galikova D; Lesko P; Obertova J; Rejlekova K; Sycova-Mila Z; Palacka P; Kalavska K; Svetlovska D; Mladosievicova B; Mardiak J; Mego M; Chovanec M
    Clin Genitourin Cancer; 2024 Jun; 22(3):102067. PubMed ID: 38555680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors.
    Eckhoff L; Knoop A; Jensen MB; Ewertz M
    Eur J Cancer; 2015 Feb; 51(3):292-300. PubMed ID: 25541155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study.
    Zhai J; Sun X; Zhao F; Pan B; Li H; Lv Z; Cao M; Zhao J; Mo H; Ma F; Xu B
    Breast; 2023 Feb; 67():36-45. PubMed ID: 36586272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence density and factors associated with peripheral neuropathy among women with breast cancer during taxane-based chemotherapy.
    Rattanakrong N; Siriphorn A; Boonyong S
    Sci Rep; 2022 Jun; 12(1):10632. PubMed ID: 35739233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
    Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
    Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction models of persistent taxane-induced peripheral neuropathy among breast cancer survivors using whole-exome sequencing.
    Engvall K; Uvdal H; Björn N; Åvall-Lundqvist E; Gréen H
    NPJ Precis Oncol; 2024 May; 8(1):102. PubMed ID: 38755266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol.
    Sharma A; Johnson KB; Bie B; Rhoades EE; Sen A; Kida Y; Hockings J; Gatta A; Davenport J; Arcangelini C; Ritzu J; DeVecchio J; Hughen R; Wei M; Thomas Budd G; Lynn Henry N; Eng C; Foss J; Rotroff DM
    Technol Cancer Res Treat; 2022; 21():15330338221127169. PubMed ID: 36172750
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
    Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry.
    Mols F; Beijers T; Lemmens V; van den Hurk CJ; Vreugdenhil G; van de Poll-Franse LV
    J Clin Oncol; 2013 Jul; 31(21):2699-707. PubMed ID: 23775951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry.
    Bonhof CS; Trompetter HR; Vreugdenhil G; van de Poll-Franse LV; Mols F
    Support Care Cancer; 2020 Dec; 28(12):5933-5941. PubMed ID: 32281032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer.
    Song SJ; Min J; Suh SY; Jung SH; Hahn HJ; Im SA; Lee JY
    Support Care Cancer; 2017 Jul; 25(7):2241-2248. PubMed ID: 28204996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer.
    Pabst L; Velten M; Fischbach C; Kalish M; Pflumio C; Pivot X; Petit T
    Breast J; 2020 Dec; 26(12):2376-2382. PubMed ID: 33307596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.
    Balayssac D; Kerckhove N; Selvy M; Pereira B; Gonneau C; Pétorin C; Vimal-Baguet A; Melnikov S; Kullab S; Hebbar M; Bouché O; Slimano F; Bourgeois V; Lebrun-Ly V; Thuillier F; Mazard T; Tavan D; Benmammar KE; Monange B; Ramdani M; Péré-Vergé D; Huet-Penz F; Bedjaoui A; Genty F; Leyronnas C; Pezet D; Martin V
    Support Care Cancer; 2024 Jun; 32(7):427. PubMed ID: 38869647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.
    Yeo F; Ng CC; Loh KWJ; Molassiotis A; Cheng HL; Au JSK; Leung KT; Li YC; Wong KH; Suen L; Chan CW; Yorke J; Farrell C; Bandla A; Ang E; Lopez V; Sundar R; Chan A
    Support Care Cancer; 2019 Dec; 27(12):4753-4762. PubMed ID: 30972646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term peripheral neuropathy symptoms in breast cancer survivors.
    Mustafa Ali M; Moeller M; Rybicki L; Moore HCF
    Breast Cancer Res Treat; 2017 Nov; 166(2):519-526. PubMed ID: 28791499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.